Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Through the neoadjuvant treatment with a combination of Cardonilli and Lenvatinib, it enabled
the successful and safe implementation of partial nephrectomy in patients with localized
renal cancer, who had indications for nephron-sparing surgery but faced considerable
difficulty in preserving the kidney (T1b with an endophytic component ≥75% or T2)